meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 2nd line (L2)
1
sarcomas
thyroid cancer
urothelial cancer (UC) - bladder cancer (BC)
gene alteration target therapy
RET gene alteration targeted therapy
pralsetinib
selpercatinib
no study with result for this clinical condition